NEWS RELEASE

BioMatrix Flex™ Approved for Reimbursement in France

Morges, Switzerland, 7 July 2011 – Biosensors International has received approval for reimbursement in France for its BioMatrix Flex™ drug-eluting stent system. The addition of BioMatrix Flex to the LPPR ("Liste des Produits et Prestations Remboursables") was published in the Journal Official on 22 June 2011. As a result of this announcement, BioMatrix Flex is now available to patients with coronary artery disease throughout France.

"We are delighted to have obtained reimbursement in France - the largest market for drug-eluting stents in Europe - for BioMatrix Flex", commented Biosensors Co-CEO Jeffrey B. Jump. "French authorities have a particularly rigorous review process and will only grant reimbursement to a product which can clearly demonstrate both clinical and economic benefits. This is further recognition for the growing body of clinical evidence that supports our innovative technology."

BioMatrix Flex offers the unique combination of Biolimus A9™ (BA9™) with a biodegradable poly-lactic acid (PLA) polymer, which is abluminally coated onto an advanced, highly flexible stent platform designed for enhanced deliverability. BA9 is an anti-restenotic drug developed and patented by Biosensors specifically for use with drug-eluting stents. It has the highest lipophilic profile of the common limus drugs, enabling rapid absorption by the tissue and minimizing systemic exposure. The PLA polymer fully degrades into carbon dioxide and water after six to nine months as it releases BA9.

BioMatrix Flex received CE Mark approval in January 2010 and is currently available in many major European, Middle Eastern, African and Asian markets. It has been approved for use in treating a comprehensive range of indications, including STEMI, Acute Coronary Syndromes and diabetes mellitus. BioMatrix Flex is available in diameters ranging from 2.25mm up to 4.00mm.

-Ends-

For further information, please contact:
Richard Kenyon
Corporate Communications
Biosensors International
+44 7831569940
r.kenyon@biosensors.com

About Biosensors International
Biosensors International develops, manufactures and markets innovative medical devices for interventional cardiology and critical care procedures. We aim to improve patients' lives through pioneering medical technology that pushes forward the boundaries of innovation.

With the increasing use of the BioMatrix™ family of drug-eluting stents, we are rapidly emerging as a leader in the global coronary stent market. The forthcoming launch of the Axxess™ self-expanding bifurcation drug-eluting stent and the development of the BioFreedom™ drug-coated stent will further reinforce our market position.

All three stents incorporate Biolimus A9™ (BA9™), an anti-restenotic drug developed and patented by Biosensors specifically for use with drug-eluting stents. Both the BioMatrix stent family and the Axxess stent feature a unique abluminal biodegradable polymer coating, which fully degrades into carbon dioxide and water after six to nine months as it releases BA9. The BioMatrix stent family features workhorse stent platforms for a broad range of lesions, and the Axxess stent employs a self-expanding stent platform specifically designed for treating bifurcation lesions. BioFreedom, a completely polymer□free stent abluminally coated with BA9, is currently undergoing clinical evaluation.

For more information, please visit www.biosensors.com.